SHIJIAZHUANG, China, March 21, 2022 /PRNewswire/ — On March 19, the Media Briefing on Prevention and Command of COVID-19 with Lianhua Qingwen Capsules, a patented Chinese drugs designed and manufactured by Yiling Pharmaceutical, was convened in Shijiazhuang Town, Hebei Province, at which the in vitro experimental success of Lianhua Qingwen Capsules versus SARS-CoV-2 Omicron variant by Guangzhou Institute of Respiratory Health not too long ago were being posted. These experimental final results present that Lianhua Qingwen Capsules have considerable inhibiting result on the cytopathic effect induced by Omicron variant so as to reach the anti-novel coronavirus influence.
Because the outbreak of the COVID-19, a sequence of essential and scientific researches on Lianhua Qingwen Capsules in opposition to SARS-CoV-2 have been carried out, forming a chain of proof for procedure of COVID-19 with Lianhua Qingwen with responsible result on “mobile-animal-scientific”. Primary investigate outcomes present that Lianhua Qingwen have secure in vitro antivirus impact on COVID-19, irrespective of whether wild-type or subsequent several mutants, can considerably strengthen the cytopathic result brought about by virus an infection, and can inhibit the release of proinflammatory factors. At current, in vitro experimental outcomes of Omicron variant have been posted, which has superior outcome. The animal experiment on Lianhua Qingwen Capsules towards Omicron is carrying out the global multicenter scientific study has been carried out in numerous countries.
The analysis benefits of “Efficacy and Basic safety of Lianhuaqingwen Capsules for the Avoidance of Coronavirus Disorder 2019: A Potential Open-Label Controlled Trial” released on the Evidence-centered Complementary and Different Medicine present that Lianhua Qingwen Capsules can significantly cut down the infection rate of shut contacts and the incidence rate of indicators for clients who are favourable in nucleic acid take a look at, specially the incidence fee of fever, so as to give new therapeutic regimens for suspected scenarios and near contacts of COVID-19.
In the Prognosis and Treatment Protocol for COVID-19 (Trial Model 9) released by Chinese federal government on March 14, Lianhua Qingwen Capsules are advised for prevention and command of the inhabitants beneath clinical observation and delicate and normal clients in the course of scientific remedy. Lianhua Qingwen Capsules have been recommended for procedure of COVID-19 for 6 moments in the nationwide protocol considering that the outbreak of COVID-19.
Check out unique written content to download multimedia:https://www.prnewswire.com/information-releases/progresses-made-in-series-of-reports-of-prevention-and-management-of-covid-19-with-lianhua-qingwen-capsules-301506432.html
Supply Yiling Pharma
